Dare Bioscience Inc (DARE)
Dare Bioscience, Inc. is a clinical-stage healthcare company focused on developing therapies in the United States across contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health. The company currently markets XACIATO, a lincosamide antibacterial gel approved for the treatment of bacterial vaginosis, and is advancing a pipeline of product candidates that includes Ovaprene, a hormone-free monthly intravaginal contraceptive, and Sildenafil Cream for topical use in treating female sexual arousal disorder. Its development programs also include candidates for menopausal symptoms, dyspareunia, HPV-related conditions, dysmenorrhea, longer-duration contraception, fertility support, preterm birth, non-hormonal contraception, live biotherapeutic delivery, and intravaginal antimicrobial treatment. Founded in 2015, Dare Bioscience is headquartered in San Diego, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DARE
|
$1.57
|
21.9% Upside
|
Undervalued
|
$9.67
|
652.3% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-1.6x
|
26.2x
|
16.6x
|
20.073 M
|
7.913 M
|
26.4%
|
91.7%
|
-10.6
|
—
|
84.6%
|
